Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12378789 | 1.00 | CTSK (0.46) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL23989898 | 0.86 | CTSK (0.46) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL2519108 | 0.86 | CTSK (0.46) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL1219074 | 0.84 | CA1 (0.51) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL1991719 | 0.84 | CA1 (0.51) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL498987 | 0.84 | CA1 (0.51) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL14632348 | 0.82 | CTSK (0.49) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL30718516 | 0.82 | CTSK (0.49) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL8893172 | 0.82 | CTSK (0.49) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL22525961 | 0.80 | CTSK (0.41) | CTSKCA1CA2CA7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | claimed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | claimed |
| US-7998961-B2 | For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | LPXN, HAX1, LCT | CTSK 1612/4885CA1 2842/4885CA2 1271/4885 |
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | CTSK 2052/4885CA1 723/4885CA2 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.